4.5 Article

microRNA 221 Targets ADAM10 mRNA and is Downregulated in Alzheimer's Disease

Journal

JOURNAL OF ALZHEIMERS DISEASE
Volume 61, Issue 1, Pages 113-123

Publisher

IOS PRESS
DOI: 10.3233/JAD-170592

Keywords

ADAM10 protein; aging; Alzheimer's disease; biomarkers; microRNAs

Categories

Funding

  1. Sao Paulo Research Foundation - FAPESP [2012/08654-7, 2013/06879-4]
  2. AIRAlzh Onlus-COOP Italia

Ask authors/readers for more resources

ADAM10 is the alpha-secretase that cleaves amyloid-beta protein precursor in the non-amyloidogenic pathway in Alzheimer's disease (AD) and is known to be regulated by different microRNAs (miRNAs), which are post-transcriptional regulators related to several biological and pathological processes, including AD. Here we proposed to explore and validate miRNAs that have direct or indirect relations to the AD pathophysiology and ADAM10 gene. Approximately 700 miRNAs were analyzed and 21 differentially expressedmiRNAs were validated in a sample of 21ADsubjects and 17 cognitively healthy matched controls. SH-SY5Y cells were transfected with miR-144-5p, miR-221, and miR-374 mimics and inhibitors, and ADAM10 protein levels were evaluated. miR-144-5p, miR-221, and miR-374 were downregulated in AD. The overexpression of miR-221 in SH-SY5Y cells resulted in ADAM10 reduction and its inhibition in ADAM10 increased. These findings show that miR-221 can be a new potential therapeutic target for increasing ADAM10 levels in AD. In addition, these results can contribute to the better understanding of ADAM10 post-transcriptional regulation.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available